Peter Knauer

Company: Xeris Pharmaceuticals

Job title: Vice President of CMC

Seminars:

Considerations for Development & Commercialization of Peptide Products 4:00 pm

Managing the evolution of dosage forms from early to late-stage development Understanding the implications of chemical and physical stability throughout the development program Evolving a target product profile (TPP) through the development program Using a novel formulation platform to achieve better TPPRead more

day: Day Two

Industry Leaders Panel Discussion: Starting With End Goals in Mind – Defining Patient-Centric Peptide Drug Delivery & Formulations to Improve Patient Adherence & Patient Outcomes 9:00 am

Using patient population characteristics to define optimal and impactful peptide therapeutic formulation and modes of administration Considering age-appropriate formulations, drug dosing, ability to self-administer, disease characteristics, disease severity, patient experience of treatment and other factors Balancing unmet patient needs with commercial value and differentiation of peptide therapeutic product formulation and deliveryRead more

day: Day One